DNMT۳A gene mutations in acute myeloid leukemia and acute lymphoid leukemia

Introduction and Aims: DNA methyltransferase۳A (DNMT۳A) is necessary for the adjustment of gene expression and the mutations in the DNMT۳A gene are reported in a variety of leukemia cases. DNMT۳A mutations are during cancer progression and cause poor prognosis in many leukemias. Thus, this gene can be as a target for new treatments. This study aimed to examine the distribution of DNMT۳A mutations in Iranian Acute leukemia patients .Materials and Methods: In this study, diagnostic samples from ۴۵ patients with de novo Acute Leukemia, including ۲۳ AML patients and ۲۲ ALL patients were screened, from May ۲۰۱۷ to February ۲۰۱۸ for incidence DNMT۳A mutations by PCR and direct sequencing .Results: A total of ۲ (۹.۱%) AML cases and ۱(۴.۳۴%) ALL case were found to have the DNMT۳A R۸۸۲H mutation .we found a total of ۲۲.۷% and ۲۱.۷% of patients with AML and ALL had polymorphism rs۳۶۸۵۱۶۵۴۳ respectively. No significant correlation was found between platelet count, Hemoglobin levels, WBC count, blast percent of bone marrow, FLT۳ mutations, CEBPA mutations, NPM۱ mutations, FAB classification, and cytogenetic abnormalities with DNMT۳A mutations. DNMT۳A mutations were considerably associated with higher age in AML patients .Conclusions: The findings suggest that the DNMT۳A mutations are probably new biomarker in the early examination and treatment of acute leukemia, although further studies are needed to assess prognosis and comparison between AML and ALL patients.

کلیدواژه ها:

Acute lymphoblastic leukemia ، Acute myeloid leukemia ، DNMT۳A mutatio